The purpose of this study is to compare the effects of trametinib with one of the standard treatments available that your doctor will choose for you (either letrozole, tamoxifen, paclitaxel, Pegylated Liposomal Doxorubicin (PLD), or topotecan) to treat your low-grade serous ovarian or peritoneal cancer to find out which works is better to control your cancer. In this study, you will get either the trametinib or one of the standard treatments available. You will not get both at the same time.
Trametinib is a new study drug intended for treating patients with cancer. It has been tested in humans with several different types of cancers and in animals. It has been approved by the U.S. Food and Drug Administration (FDA) for doctors to prescribe for patients with unresectable or metastatic melanoma with BRAFV600E or BRAFV600K mutations.
Trametinib is a drug that blocks a very important signal that controls the growth of cancer cells. It is thought that this signal is important in a variety of cancers, including low-grade serous ovarian and peritoneal cancers. Trametinib is experimental and has not yet been studied in patients with low-grade serous ovarian or peritoneal cancer.
Phase II, Phase IIIRead more